MedTrace Logo

Chemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung Cancer

NCT00686959 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 598

Last updated 2016-06-28

Study results available
· View outcomes & findings →

Summary

This study will compare the overall survival of participants with locally-advanced, Stage III Non-Small Cell Lung Cancer (NSCLC) with nonsquamous cell histology.

Conditions

  • Non Small Cell Lung Cancer

Interventions

DRUG

Pemetrexed

infusion over 10 minutes

DRUG

Cisplatin

infusion over 60 minutes with adequate anti-emetic treatment and appropriate hydration per local practice guidelines

DRUG

Etoposide

administered per local practice guidelines over a minimum of 30 minutes

DRUG

Vinorelbine

administered over 6-10 minutes infusion per local practice guidelines

DRUG

Paclitaxel

administered as a 3-hour infusion

DRUG

Carboplatin

administered per local practice guidelines over 30 minutes

RADIATION

Thoracic Radiation Therapy (TRT)

Sponsors & Collaborators

Principal Investigators

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) · Eli Lilly and Company

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-09-30
Primary Completion
2014-10-31
Completion
2014-11-30

Countries

  • United States
  • Argentina
  • Australia
  • Belgium
  • Brazil
  • Canada
  • China
  • France
  • Germany
  • Greece
  • India
  • Ireland
  • Netherlands
  • Portugal
  • South Korea
  • Spain
  • Taiwan
  • Turkey (Türkiye)
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00686959 on ClinicalTrials.gov